{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.4","upperLimit":"69.3","value":"53.7"},{"groupId":"OG001","lowerLimit":"27.7","upperLimit":"84.8","value":"58.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"DCR at Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.2","upperLimit":"55.5","value":"39.0"},{"groupId":"OG001","lowerLimit":"21.1","upperLimit":"78.9","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"DCR at Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.4","upperLimit":"67.6","value":"50.0"},{"groupId":"OG001","lowerLimit":"8.5","upperLimit":"75.5","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Intracranial DCR at Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.6","upperLimit":"59.3","value":"41.2"},{"groupId":"OG001","lowerLimit":"8.5","upperLimit":"75.5","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Intracranial DCR at Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.","dispersionType":"95% Confidence Interval","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"},{"description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.","id":"OG001","title":"ROS1 Positive Population (Phase 1)"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat (ITT) analysis set was used for overall response assessment, and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in the ITT analysis set was used for intracranial response assessment.","reportingStatus":"POSTED","timeFrame":"12 and 24 weeks","title":"Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}